1. Home
  2. CBL vs NVCR Comparison

CBL vs NVCR Comparison

Compare CBL & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBL & Associates Properties Inc.

CBL

CBL & Associates Properties Inc.

HOLD

Current Price

$42.28

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$12.19

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBL
NVCR
Founded
1978
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
CBL
NVCR
Price
$42.28
$12.19
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$45.00
$28.08
AVG Volume (30 Days)
170.9K
1.0M
Earning Date
05-04-2026
04-30-2026
Dividend Yield
4.25%
N/A
EPS Growth
132.09
21.79
EPS
4.34
N/A
Revenue
$578,373,000.00
$655,353,000.00
Revenue This Year
N/A
$7.72
Revenue Next Year
N/A
$6.74
P/E Ratio
$9.76
N/A
Revenue Growth
12.18
8.28
52 Week Low
$22.73
$9.82
52 Week High
$43.21
$20.05

Technical Indicators

Market Signals
Indicator
CBL
NVCR
Relative Strength Index (RSI) 68.63 57.94
Support Level $36.41 $10.72
Resistance Level N/A $13.78
Average True Range (ATR) 1.09 0.59
MACD 0.29 0.13
Stochastic Oscillator 83.93 91.54

Price Performance

Historical Comparison
CBL
NVCR

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: